Literature DB >> 24569776

A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia.

M W Drummond1, C Pocock2, M Boissinot3, J Mills4, J Brown5, P Cauchy6, N C P Cross7, S Hartley5, J Kell8, A Szubert5, P N Cockerill6, D T Bowen9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24569776     DOI： 10.1038/leu.2014.85

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

1.  Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.

Authors:  Joannah Score; Claire Hidalgo-Curtis; Amy V Jones; Nils Winkelmann; Alison Skinner; Daniel Ward; Katerina Zoi; Thomas Ernst; Frank Stegelmann; Konstanze Döhner; Andrew Chase; Nicholas C P Cross
Journal:  Blood       Date:  2011-11-03       Impact factor: 22.113

Review 2.  Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review.

Authors:  Michael Thorpe; Ana Montalvão; Francesca Pierdomenico; Filipa Moita; António Almeida
Journal:  Leuk Res       Date:  2012-05-17       Impact factor: 3.156

3.  Activity of azacitidine in chronic myelomonocytic leukemia.

Authors:  Rubens Costa; Haifaa Abdulhaq; Bushra Haq; Richard K Shadduck; Joan Latsko; Mazen Zenati; Folefac D Atem; James M Rossetti; Entezam A Sahovic; John Lister
Journal:  Cancer       Date:  2010-12-23       Impact factor: 6.860

4.  Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

Authors:  Thorsten Braun; Raphael Itzykson; Aline Renneville; Benoit de Renzis; François Dreyfus; Kamel Laribi; Krimo Bouabdallah; Norbert Vey; Andrea Toma; Christian Recher; Bruno Royer; Bertrand Joly; Anne Vekhoff; Ingrid Lafon; Laurence Sanhes; Guillaume Meurice; Cédric Oréar; Claude Preudhomme; Claude Gardin; Lionel Ades; Michaela Fontenay; Pierre Fenaux; Nathalie Droin; Eric Solary
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

5.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

Authors:  Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

6.  Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.

Authors:  Thomas Ernst; Andrew J Chase; Joannah Score; Claire E Hidalgo-Curtis; Catherine Bryant; Amy V Jones; Katherine Waghorn; Katerina Zoi; Fiona M Ross; Andreas Reiter; Andreas Hochhaus; Hans G Drexler; Andrew Duncombe; Francisco Cervantes; David Oscier; Jacqueline Boultwood; Francis H Grand; Nicholas C P Cross
Journal:  Nat Genet       Date:  2010-07-04       Impact factor: 38.330

7.  Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.

Authors:  Edvardas Kaminskas; Ann Farrell; Sophia Abraham; Amy Baird; Li-Shan Hsieh; Shwu-Luan Lee; John K Leighton; Hasmukh Patel; Atiqur Rahman; Rajeshwara Sridhara; Yong-Cheng Wang; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

8.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

9.  A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group.

Authors:  E Wattel; A Guerci; B Hecquet; T Economopoulos; A Copplestone; B Mahé; M E Couteaux; L Resegotti; V Voglova; C Foussard; B Pegourié; J L Michaux; E Deconinck; A M Stoppa; G Mufti; D Oscier; P Fenaux
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

10.  Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.

Authors:  Francis H Grand; Claire E Hidalgo-Curtis; Thomas Ernst; Katerina Zoi; Christine Zoi; Carolann McGuire; Sebastian Kreil; Amy Jones; Joannah Score; Georgia Metzgeroth; David Oscier; Andrew Hall; Christian Brandts; Hubert Serve; Andreas Reiter; Andrew J Chase; Nicholas C P Cross
Journal:  Blood       Date:  2009-04-22       Impact factor: 22.113
View more
  13 in total

Review 1.  Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.

Authors:  Kristen B McCullough; Mrinal M Patnaik
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

2.  5-Azacytidine depletes HSCs and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice.

Authors:  Andriyana K Bankova; Wendy W Pang; Brenda J Velasco; Janel R Long-Boyle; Judith A Shizuru
Journal:  Blood Adv       Date:  2021-10-12

Review 3.  Therapy for Chronic Myelomonocytic Leukemia in a New Era.

Authors:  Tamara K Moyo; Michael R Savona
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 4.  The blind men and the AML elephant: can we feel the progress?

Authors:  S Tauro
Journal:  Blood Cancer J       Date:  2016-05-13       Impact factor: 11.037

5.  Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia.

Authors:  Roman M Shapiro; Alejandro Lazo-Langner
Journal:  BMC Hematol       Date:  2018-01-31

6.  Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet.

Authors:  Raphael Itzykson; Pierre Fenaux; David Bowen; Nicholas C P Cross; Jorge Cortes; Theo De Witte; Ulrich Germing; Francesco Onida; Eric Padron; Uwe Platzbecker; Valeria Santini; Guillermo F Sanz; Eric Solary; Arjan Van de Loosdrecht; Luca Malcovati
Journal:  Hemasphere       Date:  2018-11-29

7.  Successful long-term treatment with azacitidine in patient with chronic myelomonocytic leukemia.

Authors:  Luka Čemažar; Helena Podgornik; Njetočka Gredelj Šimec; Samo Zver
Journal:  Hematol Rep       Date:  2020-12-02

Review 8.  Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?

Authors:  Konstantinos Liapis; Ioannis Kotsianidis
Journal:  Front Oncol       Date:  2021-12-13       Impact factor: 6.244

9.  A Case of Synchronous Bone Marrow Chronic Myelomonocytic Leukemia (CMML) and Nodal Marginal Zone Lymphoma (NMZL).

Authors:  Paolo K Soriano; Taylor Stone; Junaid Baqai; Sherjeel Sana
Journal:  Am J Case Rep       Date:  2018-09-26

10.  Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

Authors:  Matthieu Duchmann; Fevzi F Yalniz; Alessandro Sanna; David Sallman; Catherine C Coombs; Aline Renneville; Olivier Kosmider; Thorsten Braun; Uwe Platzbecker; Lise Willems; Lionel Adès; Michaela Fontenay; Raajit Rampal; Eric Padron; Nathalie Droin; Claude Preudhomme; Valeria Santini; Mrinal M Patnaik; Pierre Fenaux; Eric Solary; Raphael Itzykson
Journal:  EBioMedicine       Date:  2018-04-25       Impact factor: 8.143
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.